Serial Llama Immunization with Various SARS-CoV-2 RBD Variants Induces Broad Spectrum Virus-Neutralizing Nanobodies
Authors:
- Pavel P. SolodkovPSPavel P. Solodkov
- Alexander M. NajakshinANAlexander M. Najakshin
- Nikolai A. ChikaevNCNikolai A. Chikaev
- Sergey V. KulemzinSKSergey V. Kulemzin
- Ludmila V. MechetinaLMLudmila V. Mechetina
- Konstantin O. BaranovKBKonstantin O. Baranov
- Sergey V. GuselnikovSGSergey V. Guselnikov
- Andrey A. GorchakovAGAndrey A. Gorchakov
- Tatyana N. BelovezhetsTBTatyana N. Belovezhets
- Anton N. ChikaevACAnton N. Chikaev
- Olga Y. VolkovaOVOlga Y. Volkova
- Alexander G. MarkhaevAMAlexander G. Markhaev
Open Access
Abstract
The emergence of SARS-CoV-2 mutant variants has posed a significant challenge to both the prevention and treatment of COVID-19 with anti-coronaviral neutralizing antibodies. The latest viral variants demonstrate pronounced resistance to the vast majority of human monoclonal antibodies raised against the ancestral Wuhan variant. Less is known about the susceptibility of the evolved virus to camelid nanobodies developed at the start of the pandemic. In this study, we compared nanobody repertoires raised in the same llama after immunization with Wuhan’s RBD variant and after subsequent serial immunization with a variety of RBD variants, including that of SARS-CoV-1. We show that initial immunization induced highly potent nanobodies, which efficiently protected Syrian hamsters from infection with the ancestral Wuhan virus. These nanobodies, however, mostly lacked the activity against SARS-CoV-2 omicron-pseudotyped viruses. In contrast, serial immunization with different RBD variants resulted in the generation of nanobodies demonstrating a higher degree of somatic mutagenesis and a broad range of neutralization. Four nanobodies recognizing distinct epitopes were shown to potently neutralize a spectrum of omicron variants, including those of the XBB sublineage. Our data show that nanobodies broadly neutralizing SARS-CoV-2 variants may be readily induced by a serial variant RBD immunization.Keywords
Funding Information
- Ministry of Science and Higher Education of the Russian Federation (075-15-2021-1086, RF----193021X0015, 15.ИП.21.0015)
This publication has 30 references indexed in Scilit:
- An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive SpikeScience, 2020
- Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunizationeLife, 2020
- Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid AntibodiesCell, 2020
- Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applicationsInternational Journal of Nanomedicine, 2016
- A general protocol for the generation of Nanobodies for structural biologyNature Protocols, 2014
- Single‐Domain Antibodies and Their UtilityCurrent Protocols in Immunology, 2013
- The single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction: twenty-something years onNature Protocols, 2006
- Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neuronsBiochemical Pharmacology, 2005
- Selection and identification of single domain antibody fragments from camel heavy‐chain antibodiesFEBS Letters, 1997
- By-passing immunizationJournal of Molecular Biology, 1991